Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden

American Journal of Hematology

Volumn 84, Issue 2, 2009, Pages 102-108

  Arellano Rodrigo, Eduardo ^a   Alvarez Larrán, Alberto ^a   Reverter, Juan Carlos ^a   Colomer, Dolors ^a   Villamor, Neus ^a   Bellosillo, Beatriz ^b   Cervantes, Francisco ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANAGRELIDE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CD40 LIGAND; D DIMER; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; PADGEM PROTEIN; PHOSPHORUS; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TICLOPIDINE; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ALLELE; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; BUDD CHIARI SYNDROME; CELL ACTIVATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIUM CELL; ERYTHROMELALGIA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; JAK2 GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SPLENOMEGALY; STROKE; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE METABOLISM; THROMBOCYTHEMIA; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; WILD TYPE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; ERYTHROMELALGIA; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; POINT MUTATION; STROKE; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA; THROMBOSIS;

EID: 59949089238     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21338     Document Type: Article

References (45)

1. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22:905-914.
2. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
3. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530.
4. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175.
5. Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998;92:4446-4452.
6. Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003;92:1041-1048.
7. Lindmark E, Tenno T, Seigbahn A. Role of P-selectin and CD40 ligand in the induction of monocyte tissue factor expression. Arterioscler Thromb Vasc Biol 2000;20:2322-2328.
8. Prasad KSS, Andre P, He M, et al. Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003;100:12367-12371.
9. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-949.
10. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
11. Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40 - CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003;34:1412-1418.
12. Lowe GDO. Can haematological tests predict cardiovascular risk? The 2005 Kettle lecture. Br J Haematol 2006;133:232-250.
13. Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998;91:1288-1294.
14. Rinder HM, Tracey JB, Recht M, et al. Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost 1998;80:457-462.
15. Balduini CL, Noris P, Spedini P, et al. Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. Br J Haematol 1999;106:202-207.
16. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:181-185.
17. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99:2612-2614.
18. Musolino C, Alonci A, Bellomo G, et al. Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 2000;4:397-402.
19. André P, Hartwell D, Hrachovinová I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000;97:13835-13840.
20. del Conde I, Nabi F, Tonda R, et al. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol 2005;25:1065-1070.
21. Chakrabarti S, Varghese S, Vitseva O, et al. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005;25:2428-2434.
22. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455-2462.
23. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug? J Thromb Haemost 2006;3:245-250.
24. Kornberg A, Rahimi-Levene N, Yona R, et al. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment 1 +2levels in patients with polycythemia vera: Mechanism of activation of blood coagulation. Am J Hematol 1997;56:5-11.
25. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702-711.
26. Marchetti M, Castoldi E, Spronk HMH, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008;112:4061-4068; Prepublished on September 3, 2008, as DOI 10.1182/blood-2008-06-164087.
27. Bucalossi A, Marotta G, Bigazzi C, et al. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996;52:14-20.
28. Negaard HFS, Iversen PO, Østenstad B, et al. Increased acquired activated protein C resistance in unselected patients with hematological malignances. J Thromb Haemost 2008;6:1482-1487.
29. Jensen MK, de Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002;69:185-191.
30. Munõz-Rodríguez FJ, Reverter JC, Font J, et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus 2002;11:730-735.
31. Robertson B, Urquhart C, Ford I, et al. Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V617F status, clonality and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679-1685.
32. Boehme MWJ, Galle P, Stremmel W. Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. Immunology 2002;107:340-349.
33. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-3682.
34. Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, et al. Increased platelet, leukocyte and coagulation activation in primary myelofibrosis. Ann Hematol 2008;87:269-276.
35. Conway EM, Nowakowski B, Steiner-Mosonyi M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood 1992;80:1254-1263.
36. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006;103:6224-6229.
37. Sozer S, Wang X, Zhang W, et al. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Mol Dis 2008;41:284-291; Prepublished on August 19, 2008, as DOI 10.1016/j.bcmd. 2008.06.008.
38. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: Measuring the uncertain. Haematologica 2008;93:1412-1414.
39. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112:3135-3137.
40. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2 V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-2284.
41. Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41-48.
42. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732-2736.
43. Pemmaraju N, Moliterno AR, Williams DM, et al. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 2007;21:2210-2212.
44. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia vera study group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39.
45. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 2006;107:4139-4141.